Clearmind Medicine Stock Set to Reverse Split on Monday, October 5th (NASDAQ:CMND)

Clearmind Medicine Inc. (NASDAQ:CMND) shares are scheduled to reverse split before the market opens on Monday, October 5th. The 1-8 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.

Clearmind Medicine Trading Down 11.1%

Shares of Clearmind Medicine stock traded down $0.09 on Thursday, reaching $0.72. The company had a trading volume of 219,393 shares, compared to its average volume of 1,131,579. The firm’s 50 day moving average price is $1.39 and its two-hundred day moving average price is $3.88. The firm has a market cap of $730,116.00, a PE ratio of -0.02 and a beta of 0.94. Clearmind Medicine has a 52-week low of $0.71 and a 52-week high of $480.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 4.31.

Clearmind Medicine (NASDAQ:CMND) last issued its quarterly earnings data on Thursday, September 10th. The company reported ($0.57) EPS for the quarter.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

About Clearmind Medicine

Clearmind Medicine Inc is a biotechnology company focused on developing psychedelic-derived therapeutics for behavioral and mental health disorders. Its research programs are designed to address conditions with significant unmet medical needs, including alcohol use disorder and binge-related behaviors.

The company’s pipeline includes investigational compounds based on novel psychedelic molecules, including 5-methoxy-2-aminoindane (MEAI). Clearmind is studying these compounds for their potential to reduce harmful consumption patterns and support improved mental health outcomes.